With inflation readings, interest-rate expectations and energy prices all pulling investors in different directions, it can help to focus on clear, structural trends backed by real-world use cases. Artificial intelligence in healthcare fits that bill, with applications in diagnostics, personalised treatment, hospital efficiency and drug discovery already reshaping how care is delivered. Our Transformative AI Healthcare Stocks screener is designed to filter for companies directly exposed to this theme. In this article, you will see three stocks from that screener that illustrate different ways AI is being applied across healthcare, along with the key factors to watch on each.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Tempus AI (TEM)

Overview: Tempus AI is a US healthcare technology company that uses a large multimodal data platform, diagnostics labs and AI tools to help doctors and drug makers improve cancer and genetic care, from next generation sequencing tests and pharmacogenomic panels to software like Hub, Lens and Next for clinical decision support and research.

Operations: Tempus AI generates about US$1.36b in revenue from Medical Labs & Research services, all currently reported from the United States.

Market Cap: US$8.34b

Tempus AI sits at the intersection of genomics, AI and biopharma partnerships, with FDA cleared companion diagnostics, a fast expanding test menu and a large data licensing business that attracts companies like AstraZeneca, Gilead and Daiichi Sankyo. Recent product launches in whole genome sequencing, digital pathology and agentic AI platforms, plus raised 2026 revenue guidance, indicate how its data stack is being used in real clinical and research workflows, even as the company remains unprofitable and carries funding and reimbursement risk. Its valuation on P/S and high executive pay during loss making years suggest expectations are already high, so investors need to decide whether Tempus AI's data advantage, consortium model and AI pipeline justify that confidence or call for more caution.

Tempus AI's fast expanding data stack, FDA cleared tools and big pharma alliances hint at a much larger story than the current P/S ratio alone suggests, so line up the expectations against the underlying assumptions with the DCF valuation analysis for Tempus AI

Insmed (INSM)

Overview: Insmed develops and commercializes therapies for serious and rare respiratory and neuromuscular diseases, anchored by ARIKAYCE for difficult lung infections and a late stage pipeline that includes brensocatib for bronchiectasis, treprostinil palmitil for pulmonary hypertension and several gene and antibody programs.

Operations: Insmed generates about US$819.6m in revenue from therapies for patients with rare diseases, with around US$658.7m from the United States and US$160.8m from international markets.

Market Cap: US$20.42b

Insmed offers investors a focused respiratory story, with ARIKAYCE already on the market and Brinsupri (brensocatib) being evaluated as a potential standard treatment in non cystic fibrosis bronchiectasis, supported by positive Phase III data, strong physician interest and early launch traction. Analyst forecasts highlight expectations for revenue and earnings growth, and management is targeting cash flow positivity in 2027 with about US$1.2b in cash to fund ongoing R&D and international launches. The stock is described by some observers as trading below certain fair value estimates despite a rich P/S multiple. However, Insmed is currently loss making, relies heavily on external funding and has recently diluted shareholders, so the investment case depends on whether the bronchiectasis and ARIKAYCE expansion story is sufficient to offset those financial and regulatory risks.

Insmed’s respiratory story is accelerating, with enthusiasm around Brinsupri and ARIKAYCE expansion often masking key funding and dilution questions. Pressure test the full picture with the analysis report for Insmed

Stryker (SYK)

Overview: Stryker is a global medical technology company that supplies hospitals and surgeons with orthopedic implants, surgical equipment, neurotechnology devices and an AI assisted virtual care and clinical communication platform used in operating rooms and acute care settings.

Operations: Stryker generates about US$9.47b in revenue from Orthopaedics and US$15.80b from MedSurg and Neurotechnology, with around US$19.04b of revenue reported from the United States and a US$6.23b segment adjustment.

Market Cap: US$117.18b

For investors looking at AI in healthcare, Stryker brings together smart robotics, connected SmartHospital infrastructure and AI supported virtual care on top of a large base of orthopedic and MedSurg products, with Q1 2026 revenue at US$6.02b and net income at US$745m. Earnings growth has recently outpaced much of the Medical Equipment sector and analysts see further upside, yet the stock still trades on a richer P/E and carries clear trade offs, including high debt, tariff exposure and fresh integration work from deals like Amplitude Vascular. Add in recent insider selling and a relatively new management team, and you have a high quality compounder candidate. The real question is whether execution, margins and AI driven hospital digitization can keep justifying that premium.

Stryker’s AI fueled hospital story is gaining attention, but the premium price tag and balance sheet choices are easy to gloss over. Before you decide the trade off is worth it, walk through the 4 key rewards and 2 important warning signs

The three stocks in this article are just a starting point, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaced 36 more companies with equally compelling AI in healthcare narratives waiting to be unpacked. Use Simply Wall St to identify and analyze the specific catalysts and storylines that matter to you so you can filter this wider group down to the highest conviction ideas for your watchlist.

Take Control of Your Investment Journey

If Stryker or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh stock ideas do not stay under the radar for long. Once momentum hits, entry points can start flying. Scan these focused lists before the crowd and act now.

• Catch potential early breakouts among smaller AI leaders by running through 31 AI small caps, a tight set of companies already pushing practical applications beyond headline hype.
• Pursue resilient cash flow and balance sheet strength with the list of solid balance sheet and fundamentals (46 results), curated to spotlight stocks where financial footing supports the story while it still matters.
• Target income opportunities while prices are still settling using the 9 dividend fortresses, featuring companies that pair higher yields with business models designed to keep distributing cash.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.